Melanoma Approvals Break New Ground In Immunotherapy

First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.

More from Clinical Trials

More from R&D